Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company, has entered a collaboration with Geisinger to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes.
The three type 2 diabetes-related common health outcomes include cardiovascular death, kidney failure and hospitalisation for heart failure.
The new model will enable healthcare professionals to identify the adult patients with type 2 diabetes who are at maximum risk of developing the serious and costly health consequences.
Boehringer Ingelheim Pharmaceuticals Market Access vice-president Christine Marsh said: “We believe this initiative to develop a predictive risk model is very timely, as recent research has provided more practical knowledge about how to reduce cardiovascular risk in people with type 2 diabetes.”
The model will be created using Geisinger’s de-identified electronic health record data, including demographics, vital signs, medical history, current medications and laboratory tests.
It will help develop precise treatment pathways for patients with type 2 diabetes that align with quality guidelines focused on improving patient outcomes, quality and total cost of care.
Geisinger Epidemiology assistant professor Brent Williams said: “Our partnership with Boehringer Ingelheim will use real-world data and predictive modelling to deploy precision healthcare strategies to bring the most value to the people we care for.
“We hope the knowledge gained from this predictive model can help healthcare providers better target their treatment recommendations for people with type 2 diabetes and, as a result, lower their risk for these serious diabetes-related consequences.”
In January 2011, Boehringer Ingelheim formed an alliance with Lilly for diabetes.